ArticleJournal of hematology2026
Abnormal Eosinophils With Large, Distinctly Basophilic Granules (Harlequin Cells) on Peripheral Blood Smear: A Clue for Diagnosing Chronic Myeloid Leukemia.
Article in Journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic myeloid leukemia (CML) often presents with hematologic findings that overlap with reactive leukocytosis and other myeloproliferative neoplasms (MPNs), creating diagnostic uncertainty that may delay targeted therapy or prompt unnecessary molecular testing. Harlequin cells-abnormal eosinophils containing basophilic granules-are well described in acute myeloid leukemia (AML) with Methods: We retrospectively reviewed 177 peripheral blood smears: 53 CML; 30 non-CML MPN and related disorders; 59 AML (including three with Results: Harlequin cells were identified in 72% (38 out of 53) of CML cases, a frequency significantly higher than in non-CML MPN (10%, P < 0.01), AML without Conclusions: In the appropriate clinical context, strictly defined Harlequin cells on routine peripheral blood smears may serve as a sensitive and highly specific morphologic clue for CML. Recognition of this readily accessible feature may facilitate prompt
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.